Transperineal Irreversible Electroporation for Benign Prostatic Hyperplasia

NCT06867315 · tracked via the Priya Life Science China tracker

Sponsor

First Affiliated Hospital of Zhejiang University

Phase

Not applicable

Started

2024-09-11

Last updated

2026-10-14

Condition(s) studied

Benign Prostatic Hyperplasia

Investigational drug(s) / intervention(s)

Composite steep-pulse therapeutic device (CNP-III)

Composite steep-pulse therapeutic device (CNP-III): Electrodes are inserted percutaneously into the bilateral transition zones of the prostate via a transperineal approach under real-time transrectal ultrasound guidance with a biplane probe; freehand or perineal template placement is permitted by the protocol. A minimum distance of 0.5 cm is maintained from the urethra, the prostatic apex, and the rectum; needle spacing is 1.0-2.2 cm; the effective exposed electrode length is 1.5, 2.0, or 2.5 cm. Ablation is performed in the high-frequency or low-frequency mode, with ablation parameters adjusted according to the delivered current. The ablation range is assessed intraoperatively by contrast-enhanced ultrasound. Procedures are performed under general anaesthesia, neuraxial anaesthesia, or intravenous sedation combined with local anaesthesia. An indwelling urinary catheter is placed before the procedure.

Study summary

This clinical trial focuses on men with benign prostatic hyperplasia (BPH), a condition in which an enlarged prostate causes urinary problems. The goal is to test a non-thermal ablation technique called irreversible electroporation (IRE), delivered with a steep pulse therapy system, for treating BPH.

The main questions it aims to answer are:

1. How many participants have improved urine flow 3 months after treatment?
2. How do urinary symptoms, quality of life, and prostate size change after treatment?
3. What side effects occur, and how serious are they?

Participants will be asked to:

* undergo the IRE procedure: needle electrodes are placed in the prostate through the perineum under ultrasound guidance, and short electric pulses ablate the enlarged tissue;
* attend follow-up visits at 1 and 3 months after the procedure for urine flow tests, symptom questionnaires, and ultrasound measurements.

Eligibility

Sex

MALE

Min age

50 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. patients with BPH diagnosed through digital rectal examination, B-mode ultrasound and urinary flow rate. 2. international prostate symptom score(IPSS)\>=12. 3. Maximum urinary flow rate between \>5ml/s and \<15ml/s with a minimum voided volume ≥ 150ml. 4. Age ≥ 50 years old. 5. Subjects are willing to participate and have signed the informed consent form. Exclusion Criteria: 1. Patients with acute or severe urinary tract infections. 2. Patients clinically diagnosed with prostate cancer. 3. Patients with neurogenic bladder or bladder dysfunction due to other factors. 4. Patients with urethral stricture. 5. Patients who have undergone previous prostatectomy (TURP), enucleation, or laser surgery. 6. Patients with implanted pacemakers or metal replacements in the pelvis or hip joints. 7. Patients who cannot tolerate general anesthesia or surgery due to severe systemic diseases, heart diseases, pulmonary insufficiency, failure of vital organs, or other reasons. 8. Patients in the trial group who have taken medications that can affect BPH symptoms within 3 months of postoperative follow-up. 9. Patients who have participated in other drug trials or medical device clinical trials within 3 months prior to enrollment. 10. Patients deemed unsuitable for participation in this clinical trial by the investigator.

Primary outcome measure(s)

The change in maximum urinary flow rate — 3 months
compare the maximum urinary flow rate of the patients post treatment to the baseline level of the patients

Trial sites (10)

Facility	City	Region	Status
The First Affiliated Hospital of University of Science and Technology of China	Hefei	Anhui	Recruiting
Fujian Provincial Hospital	Fuzhou	Fujian	Recruiting
Quanzhou First Hospital	Quanzhou	Fujian	Recruiting
Zhongshan Hospital Affiliated to Xiamen University	Xiamen	Fujian	Recruiting
Zhangzhou Hospital of Fujian Province	Zhangzhou	Fujian	Recruiting
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University	Shanghai	Shanghai Municipality	Recruiting
Shanghai Tenth People's Hospital	Shanghai	Shanghai Municipality	Recruiting
Shanghai Jiading District Central Hospital	Shanghai	Shanghai Municipality	Recruiting
The First Affiliated Hospital of Zhejiang University	Hangzhou	Zhejiang	Recruiting
Hangzhou First People's Hospital	Hangzhou	Zhejiang	Recruiting

More First Affiliated Hospital of Zhejiang University trials in China

First-Line Jaktinib for Acute Graft-Versus-Host Disease (aGVHD) Recruiting

Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT Recruiting

Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML Recruiting

Remimazolam for Bronchoscopy in High-Risk Patients Recruiting

Stereotactic Aspiration of Brain Stem Hematoma Starting soon

Other trials for the same condition

Modified Water Vapor Thermal Therapy in Management of Patients With Large-volume Benign Prostatic Hyperplasia Starting soon

A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia Starting soon

Thulium Laser Enucleation With Bladder Neck Incision for Small-Volume Benign Prostatic Hyperplasia Starting soon

Ultrasound-Guided vs. Conventional Prostate Suspension in BPH: An Exploratory Study Starting soon

MRI-DTI Assessment of Urethral Internal Sphincter Ring and Prostate Base Morphology Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06867315 on ClinicalTrials.gov ↗ ← All trials in China